Invasive pneumococcal disease in infants younger than 90 days before and after introduction of PCV7

Pediatrics

Volumn 132, Issue 1, 2013, Pages

  Olarte, Liset ^a   Ampofo, Krow ^a   Stockmann, Chris ^a   Mason, Edward O ^b   Daly, Judy A ^a   Pavia, Andrew T ^a   Byington, Carrie L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Infant; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ABSCESS; AGE DISTRIBUTION; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL PERITONITIS; CELLULITIS; CHILD DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EMPYEMA; FEMALE; HUMAN; INCIDENCE; INFANT; INTENSIVE CARE; MALE; MASTOIDITIS; MYOSITIS; NEWBORN; OSTEOMYELITIS; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; UNITED STATES; VACCINATION;

EID: 84879973445     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-3900     Document Type: Article

References (46)

1. O'Brien KL, Wolfson LJ, Watt JP, et al Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet. 2009;374(9693):893-902
2. American Academy of Pediatrics Committee on Infectious Diseases. Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106(2 pt 1):362-366
3. Whitney CG, Farley MM, Hadler J, et al Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348 (18):1737-1746
4. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113(3 pt 1):443-449
5. Pilishvili T, Lexau C, Farley MM, et al Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41
6. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144-148
7. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis. 2008;47(8):989-996
8. Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine. 2007;25 (13):2420-2427
9. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295(14):1668-1674
10. Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and Wales. Clin Infect Dis. 2013;56(5):633-640
11. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269(2):221-226
12. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840-847
13. Ampofo K, Pavia AT, Chris S, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: A case for continuous surveillance. Pediatr Infect Dis J. 2012;31(3):228-234
14. Byington CL, Samore MH, Stoddard GJ, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: Emergence of nonvaccine serogroups. Clin Infect Dis. 2005;41(1):21-29
15. Centers for Disease Control and Prevention. Statistics and surveillance: Immunization coverage in the U.S. 2011. Available at: Www.cdc.gov/vaccines/ stats-surv/imz-coverage. htm#nis. Accessed September 11, 2012
16. Centers for Disease Control and Prevention. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine-United States, 2007. MMWR Morb Mortal Wkly Rep. 2010;59(9):253-257
17. Utah Department of Health. Indicator-based information system for public health (IBISPH). Available at: Http://ibis.health.utah.gov/home. Accessed September 11, 2012
18. Bruyere PT, Bruyere MC, Gleeson GA. The use of 2 x n chi square in the analysis of change in age distributions. Am J Public Health Nations Health. 1946;36:510-514
19. Shah SS, Ratner AJ. Trends in invasive pneumococcal disease-associated hospitalizations. Clin Infect Dis. 2006;42(1):e1-e5
20. Haddy RI, Perry K, Chacko CE, et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2005;24(4):320-323
21. Hoffman JA, Mason EO, Schutze GE, et al. Streptococcus pneumoniae infections in the neonate. Pediatrics. 2003;112(5):1095-1102
22. Imöhl M, van der Linden M, Mutscher C, Reinert RR. Serotype distribution of invasive pneumococcal disease during the first 60 days of life. Vaccine. 2010;28(30): 4758-4762
23. Ashkenazi L, Bar-Meir M, Schlesinger Y, Megged O. Invasive pneumococcal disease in infants younger than 60 days. Clin Pediatr (Phila). 2012;51(5):478-482
24. Centers for Disease Control and Prevention. National Vital Statistics Reports. Births: Preliminary data for 2008. Available at: Www.cdc. gov/nchs/data/nvsr/nvsr58/nvsr58-16-tables. pdf#d. Accessed March 18, 2013
25. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease: Revised guidelines from CDC. MMWR Recomm Rep. 2002;51(RR-11): 1-22
26. Glasgow TS, Speakman M, Firth S, James B, Byington CL, Young PC. Clinical and economic outcomes for term infants associated with increasing administration of antibiotics to their mothers. Paediatr Perinat Epidemiol. 2007;21(4):338-346
27. Balmer P, Borrow R, Findlow J, et al. Agestratified prevalences of pneumococcalserotype-specific immunoglobulin G in England and their relationship to the serotypespecific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol. 2007;14(11):1442-1450
28. Shahid NS, Steinhoff MC, Hoque SS, Begum T, Thompson C, Siber GR. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet. 1995;346(8985):1252-1257
29. Ampofo K, Pavia AT, Stockmann CR, et al. Evolution of the epidemiology of pneumococcal disease among Utah children through the vaccine era. Pediatr Infect Dis J. 2011;30(12):1100-1103
30. Haddad MB, Porucznik CA, Joyce KE, et al. Risk factors for pediatric invasive pneumococcal disease in the Intermountain West, 1996-2002. Ann Epidemiol. 2008;18(2): 139-146
31. Millar EV, O'Brien KL, Zell ER, Bronsdon MA, Reid R, Santosham M. Nasopharyngeal carriage of Streptococcus pneumoniae in Navajo and White Mountain Apache children before the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2009;28(8):711-716
32. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics. 2009;124(1). Available at: Www.pediatrics.org/cgi/content/full/124/1/e1
33. Tigoi CC, Gatakaa H, Karani A, et al. Rates of acquisition of pneumococcal colonization and transmission probabilities, by serotype, among newborn infants in Kilifi District, Kenya. Clin Infect Dis. 2012;55(2):180-188
34. Hill PC, Cheung YB, Akisanya A, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: A longitudinal study. Clin Infect Dis. 2008;46(6):807-814
35. Turner P, Turner C, Jankhot A, et al. A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS ONE. 2012;7(5):e38271
36. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196(9):1346-1354
37. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: A study from a Children's Hospital Emergency Department and Urgent Care Center. Arch Pediatr Adolesc Med. 2004;158 (7):671-675
38. Carstairs KL, Tanen DA, Johnson AS, Kailes SB, Riffenburgh RH. Pneumococcal bacteremia in febrile infants presenting to the emergency department before and after the introduction of the heptavalent pneumococcal vaccine. Ann Emerg Med. 2007;49(6):772-777
39. Benito-Fernández J, Mintegi S, Pocheville-Gurutzeta I, Sánchez Etxaniz J, Gómez Cortés B, Hernández Almaraz JL. Pneumococcal bacteremia in febrile infants presenting to the emergency department 8 years after the introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. Pediatr Infect Dis J. 2010;29(12):1142-1144
40. Bressan S, Berlese P, Mion T, Masiero S, Cavallaro A, Da Dalt L. Bacteremia in feverish children presenting to the emergency department: A retrospective study and literature review. Acta Paediatr. 2012;101(3): 271-277
41. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429-436
42. Imöhl M, Reinert RR, Ocklenburg C, van der Linden M. Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J Clin Microbiol. 2010;48(4):1291-1296
43. Kaltoft ZN, Zeuthen N, Konradsen HB. Epidemiology of invasive pneumococcal infections in children aged 0-6 years in Denmark: A 19-year nationwide surveillance study. Acta Paediatr Suppl. 2000;89(435):3-10
44. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197 (7):1016-1027
45. Rückinger S, von Kries R, Siedler A, van der Linden M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J. 2009; 28(2):118-122
46. Chudwin DS, Wara DW, Schiffman G, Artrip SG, Ammann AJ. Maternal-fetal transfer of pneumococcal capsular polysaccharide antibodies. Am J Dis Child. 1985;139(4):378-380